Kazakhstan Medical Device Registration: Changing the Authorized Representative

1. Key takeaways

Kazakhstan imposes one hard limit on representation: only one authorized representative may be designated for each medical device or medical equipment item. The manufacturer may replace the representative, but it must formally notify the competent authority and obtain approval of the change to the registration certificate. Until this procedure is completed, the new representative cannot lawfully act, and the old representative remains the obligated party in the regulatory records. Replacing the representative also requires a synchronized update of the representative information on labels and instructions for use, together with a transition plan for packaging materials. A gap at any link of this chain creates a compliance defect in which the register and the physical product no longer match. The practical estimate is that a representative change touches legal, regulatory, labeling and supply chain workstreams at the same time, so it should be run as a project with a single owner rather than as a set of parallel tasks owned by different departments.

2. Legal basis

3. Expert insights

Insight one: one device, one representative is a numerical limit and also a source of commercial risk. The representative is recorded on the registration certificate, so the manufacturer needs the consent and cooperation of the original representative when changing sales channels. If the original representative does not cooperate, the manufacturer can only apply for registration again, which amounts to discarding the compliance investment already made. This is the risk that most needs to be contractually mitigated in advance in Kazakhstan projects. In practice, the mitigation package includes cooperation duties during the change, a duty to sign amendment documents within a defined period, and a duty to hand over correspondence and regulatory files on exit.

Insight two: changing the representative is a three-track synchronized action. The change of the registration certificate, the update of the label and instructions for use, and the transition of packaging materials must proceed in step. If only the first step is taken while the other two are ignored, the market will continue to carry products labeled with the old representative while the register already names the new one, an obvious mismatch. The mismatch is exactly what market surveillance and customs checks look for, and it can trigger suspension of supply until the physical stock is aligned with the register.

Insight three: the change window and the timing of the representative change must be linked. Under the protocol signed on December 29, 2025, the window for submitting change applications under national rules closes on December 31, 2028. Companies planning a representative change should complete it before that date where possible; after that point, changes must be handled under Union rules. Planning backward from that date, manufacturers should allow time for the certificate amendment itself, for reprinting packaging materials and for selling through or relabeling existing stock, so the decision point for starting the change falls considerably earlier than the deadline.

Insight four: the obligations of the representative truly begin after certification. The timing of a representative change must take into account the handover of post-market obligations: adverse event monitoring, regulatory responses and handling of market complaints. If the new representative lacks the capacity to absorb these duties, the change creates a vacuum of obligations instead of solving a problem. A structured handover covering open vigilance cases, pending authority correspondence and complaint histories is therefore part of the change plan, not an optional courtesy between the outgoing and incoming representatives.

Insight five: a change of representative does not affect the holder status of the manufacturer. The manufacturer always remains the holder of the registration certificate. This structure means that replacing a representative is technically feasible; the difficulty lies in procedure and commercial cooperation, not in legal status. This is why the practical estimate of effort for a representative change is dominated by documentation and coordination rather than by any legal barrier to the transfer itself.

4. Practical recommendations

1. Write the cooperation obligations, change procedure and exit mechanism of the representative into the appointment agreement at the drafting stage, and agree on liability for breach.
2. Advance a representative change on three synchronized tracks: amendment of the registration certificate, update of labels and instructions for use, and transition of packaging materials.
3. If a change is planned, schedule it for completion before December 31, 2028.
4. Assess the capacity of the new representative to absorb post-market obligations, including monitoring, regulatory response and complaint handling.
5. After the change is completed, verify that the register record and the physical labels are consistent.

5. Verification checklist

• □ The appointment agreement contains cooperation obligations, a change procedure and an exit mechanism
• □ The representative change has been formally notified to the competent authority and the certificate amendment approved
• □ Representative information on labels and instructions for use has been updated in sync
• □ A packaging material transition plan has been prepared and executed
• □ The change has been arranged for completion before December 31, 2028
• □ After completion, the register record and the physical labels have been checked for consistency

Regulatory information verified as of October 29, 2026.

GRZAN provides registration support in Kazakhstan for medical device manufacturers, importers and authorized representatives, including representative appointment, change filings and post-market compliance. Change projects are managed as coordinated legal, regulatory and labeling workstreams with a single timeline. For inquiries, contact info@grzanglobal.com.